Evidence map›Paper›PMID 36614249›Full record

ArticleInternational journal of molecular sciences2023

RPS24 Is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma.

Haiyuan Li, Lei Gao, Xiaojuan Kang, Xueyan Wang, Yang Yu, Yaqing Zhang, Hao Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Haiyuan LiSecond Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Lei GaoSecond Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Xiaojuan KangSecond Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Xueyan WangSecond Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Yang YuSecond Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Yaqing ZhangSecond Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Hao ChenSecond Clinical Medical College, Lanzhou University, Lanzhou 730000, China.ORCID 0000-0003-0018-480X
Lanzhou University Second Hospital · CN

Funding

Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital 2020QN-06Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital CY2017-ZD01Cuiying Scientific Training Program for Undergraduates of Lanzhou University Second Hospital CYXZ2021-45Gansu Province Higher Education Innovation Fund Project 2021B-044Key Project of Science and Technology in Gansu province 19ZD2WA001the Key Talents Project of Gansu Province 2019RCXM020
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common type of primary liver malignancy, with increased mortality and morbidity. Accumulating evidence suggested that 40S ribosomal protein S24 (RPS24) is related to malignant outcomes and progression. However, the role of RPS24 remains unclear in HCC. The mRNA and protein expression pattern of RPS24 in HCC was explored and confirmed based on the bioinformatics analysis and histological examination. The correlation between RPS24 expression and clinicopathological features, diagnostic value, prognosis, methylation status, and survival were evaluated. Then, we divided the HCC cohort into two groups based on the expression of RPS24, and performed the functional enrichment and immune cells infiltration analysis of RPS24. Furthermore, in vivo and in vitro experiments were performed to investigate the effect of RPS24 on HCC cells. RPS24 was observed to be elevated in HCC samples. RPS24 overexpression or RPS24 promoter methylation contributed to an unfavorable prognosis for HCC patients. The genes in the high RPS24 expression group were mainly enriched in DNA replication, cell cycle E2F targets, and the G2M checkpoint pathway. Moreover, the expression level of RPS24 was significantly related to immune infiltration and immunotherapy response. Our experiments also demonstrated that RPS24 knockdown suppressed the growth of HCC cells and tumor proliferation of the xenograft model. Therefore, RPS24 can be a potential adverse biomarker of HCC prognosis acting through facilitating cell proliferation and the formation of an immunosuppressive microenvironment in HCC. Targeting RPS24 may offer a promising therapeutic option for HCC management.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCell CycleCell DivisionHumansRibosomal ProteinsTumor MicroenvironmentRibosomal ProteinsRPS24 protein, humancell proliferationhepatocellular carcinomaimmune infiltrationprognosisRPS24

Identifiers

PMID36614249
PMCPMC9820840
OpenAlexW4313516466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.